

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED**

### **領航醫藥及生物科技有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock Code: 399)**

## **VOLUNTARY ANNOUNCEMENT**

This announcement is made by Innovative Pharmaceutical Biotech Limited (the “**Company**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) wishes to inform shareholders and potential investors of the Company that, the Company has received an invitation (the “**Invitation**”) from Ming International Travel Investment (Beijing) Corp.\* (明游天下國際旅游投資(北京)股份有限公司) (“**Ming Travel**”), an independent third party and a company incorporated in the People’s Republic of China principally engaged in tourism and trip planning, to participate in the subscription of new shares in Mangocity.com (Investment) Limited (芒果網(投資)有限公司) (the “**Target Company**”), a company incorporated in Hong Kong and an indirect wholly-owned subsidiary of The China National Travel Service (HK) Group Corporation\*, China’s largest travel group. Pursuant to the Invitation, the Company is informed that Ming Travel had, among others, entered into an agreement with the Target Company to conditionally subscribe for an aggregate of 39% new shares of the Target Company (the “**Ming’s Investment**”). With all the necessary approval and consent required pursuant to relevant laws and regulations having been obtained, Ming Travel indicated its intention to invite the Company to participate in the Ming’s Investment (the “**Potential Transaction**”).

Upon preliminary assessment of the Potential Transaction, the Board has resolved to initiate preliminary negotiation with Ming Travel and the Target Company in relation the Company’s participation in the Potential Transaction.

As at the date of this announcement, the Company has merely resolved to initiate preliminary negotiation with Ming Travel and the Target Company in relation to the Potential Transaction and no concrete terms have been agreed and no definitive agreement has been entered into by the Company in relation to the Potential Transaction. If the Potential Transaction materialises, it may constitute a notifiable transaction for the Company under the Rules Governing the Listing of Securities of the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Further announcement(s) in relation to the Potential Transaction will be made by the Company as and when appropriate in compliance with the Listing Rules.

**The shareholders and potential investors of the Company should note that there is no assurance that the Potential Transaction and any transaction referred to in this announcement will be materialised, shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Innovative Pharmaceutical Biotech Limited**  
**Tang Rong**  
*Executive Director*

Hong Kong, 4 March 2016

*As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive director), Mr. Gao Yuan Xing (executive director), Mr. Tang Rong (executive director), Ms. Xiao Yan (non-executive director), Ms. Wu Yanmin (non-executive director), Ms. Chen Weijun (independent non-executive director), Dr. Zhang Zhihong (independent non-executive director) and Mr. Wang Rongliang (independent non-executive director).*

\* *For identification purpose only*